Evidence map›Paper›PMID 38703782›Full record

ArticleThe Lancet. Microbe2024

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.

Susan Jackson, Julia L Marshall, Andrew Mawer, Raquel Lopez-Ramon, Stephanie A Harris, Iman Satti, Eileen Hughes, Hannah Preston-Jones, Ingrid Cabrera Puig, Stephanie Longet and 20 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Microbe, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Susan JacksonDepartment of Paediatrics, University of Oxford, Oxford, UK.
Julia L MarshallDepartment of Paediatrics, University of Oxford, Oxford, UK; The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC, Australia.
Andrew MawerDepartment of Paediatrics, University of Oxford, Oxford, UK.
Raquel Lopez-RamonDepartment of Paediatrics, University of Oxford, Oxford, UK.
Stephanie A HarrisDepartment of Paediatrics, University of Oxford, Oxford, UK.
Iman SattiDepartment of Paediatrics, University of Oxford, Oxford, UK.
Eileen HughesDepartment of Paediatrics, University of Oxford, Oxford, UK.
Hannah Preston-JonesDepartment of Paediatrics, University of Oxford, Oxford, UK.
Ingrid Cabrera PuigDepartment of Paediatrics, University of Oxford, Oxford, UK.
Stephanie LongetThe Wellcome Centre for Human Genetics and Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Tom TiptonThe Wellcome Centre for Human Genetics and Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Stephen LaidlawThe Wellcome Centre for Human Genetics and Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Rebecca Powell DohertyDepartment of Paediatrics, University of Oxford, Oxford, UK.
Hazel MorrisonDepartment of Paediatrics, University of Oxford, Oxford, UK.
Robert MitchellDepartment of Paediatrics, University of Oxford, Oxford, UK.
Rachel TannerDepartment of Paediatrics, University of Oxford, Oxford, UK.
Alberta AteereDepartment of Paediatrics, University of Oxford, Oxford, UK.
Elena StylianouDepartment of Paediatrics, University of Oxford, Oxford, UK.
Meng-San WuDepartment of Paediatrics, University of Oxford, Oxford, UK.
Timothy P W Fredsgaard-JonesDepartment of Paediatrics, University of Oxford, Oxford, UK.
Judith BreuerInstitute of Child Health, University College London, London, UK.
Garth RapeportNational Heart and Lung Institute, Imperial College London, London, UK.
Vanessa M FerreiraRadcliffe Department of Medicine, University of Oxford, Oxford, UK.
Fergus GleesonOxford Radiology Research Unit, University of Oxford, Oxford, UK.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Miles CarrollThe Wellcome Centre for Human Genetics and Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Andrew CatchpolehVIVO, London, UK.
Christopher ChiuDepartment of Infectious Disease, Imperial College London, London, UK.
Helen McShaneDepartment of Paediatrics, University of Oxford, Oxford, UK. Electronic address: helen.mcshane@ndm.ox.ac.uk.
COV-CHIM01 study team

Funding

Medical Research Council MR/X009297/1Wellcome Trust 222305
6 · The paper itself

Abstract

backgroundA SARS-CoV-2 controlled human infection model (CHIM) has been successfully established in seronegative individuals using a dose of 1×10

methodsHealthy, UK volunteers aged 18-30 years, with proven (quantitative RT-PCR or lateral flow antigen test) previous SARS-CoV-2 infection (with or without vaccination) were inoculated intranasally in a stepwise dose escalation CHIM with either 1×10

findingsRecruitment commenced on May 6, 2021, with the last volunteer enrolled into the dose escalation cohort on Nov 24, 2022. 36 volunteers were enrolled, with four to eight volunteers inoculated in each dosing group from 1×10

interpretationOur study demonstrates potent protective immunity induced by homologous vaccination and homologous or heterologous previous SARS-CoV-2 infection. The community breakthrough infections seen with the omicron variant supports the use of newer variants to establish a model with sufficient rate of infection for use in vaccine and therapeutic development.

fundingWellcome Trust and Department for Health and Social Care.

Indexed as

Antibodies, ViralCOVID-19SARS-CoV-2AdolescentAdultAntibodies, NeutralizingCOVID-19 VaccinesFemaleHealthy VolunteersHumansMaleUnited KingdomVaccinationYoung AdultAntibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccines

Identifiers

PMID38703782
PMCPMC7616636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.